Mesoblast recently announced positive results from the placebo-controlled Phase 2 trial of its cell therapy MPC-300-IV for diabetic kidney disease patients. All results can be found in the paper “Allogeneic Mesenchymal Precursor Cells (MPC) in Diabetic Nephropathy: A Randomized, Placebo Controlled, Dose Escalation Study,” published in the journal EBioMedicine. The clinical trial, conducted by researchers at the University...